Anti-c-myc cholesterol based lipoplexes as onco-nanotherapeutic agents in vitro

Background: Strategies aimed at inhibiting the expression of c-myc oncogene could provide basis for alternative cancer treatment. In this regard, silencing using small interfering RNA (siRNA) is an attractive option. However, development a clinically viable, siRNA-based, system largely dependent upon design appropriate siRNA carrier that can be easily prepared. Nanostructures formed by electrostatic association and cationic lipid vesicles represent uncomplicated delivery systems. Methods: This study has focused on liposomes prepared with equimolar quantities cytofectin, N,N-dimethylaminopropylamido-succinylcholesteryl-formylhydrazide (MS09), cholesterol (Chol) simple, but effective anti- onco-nanotherapeutic agent. Liposomes formulated dioleoylphosphatidylethanolamine (DOPE) in place Chol as co-lipid were included comparative purposes. Results: successfully bound forming lipoplexes less than 150 nm size, which assumed bilamellar aggregrates. The liposome formulations well tolerated human breast adenocarcinoma (MCF-7) colon carcinoma (HT-29) cells, overexpress c-myc. Lipoplexes directed against transcript mediated dramatic reduction mRNA protein levels. Moreover, knockdown anti-cancer effects superior to Lipofectamine™ 3000. Conclusion: MS09:Chol lipoplex exemplifies simple anticancer agent enhanced gene potential in vitro